Mark J. Enyedy Senior Vice President; President, Transplant, Oncology & Multiple Sclerosis Mark Enyedy joined Genzyme in 1996. He oversees the company’s growing Transplant and Oncology business unit as well as the program to develop and commercialize alemtuzumab for Multiple Sclerosis. He is also responsible for managing mergers and acquisitions, product licensing and corporate partnering transactions for these businesses. Before joining Genzyme, Mr. Enyedy practiced law at Palmer & Dodge, a Boston law firm, where he represented a number of clients in the biopharmaceutical industry in acquisition, partnering and financing transactions. Mr. Enyedy received a J.D. from Harvard Law School and a B.S. from Northeastern University.